| Abstrakt: |
The rest ten questions were on: AZM dispensing with or without prescription; AZM storage by pharmacies in Jordan before and during the COVID-19 pandemic; the pharmacist's belief that AZM could have a positive effect on COVID-19; and if AZM use for viral infections has negative consequences. After screening FDA-approved chemical library, a group from France demonstrated that Azithromycin (AZM) exhibited the highest in vitro anti-SARS-CoV-2 activity.[5] AZM is a second-generation, broad-spectrum, synthetic macrolide antibiotic that inhibits protein synthesis.[6] However, it has been shown that AZM has anti-SARS-CoV-2 activities,[5],[7],[8] as well as anti-inflammatory properties, mainly by inhibiting dysregulated production of proinflammatory cytokines.[8],[9] Furthermore, AZM has been used for treating several previous SARS and Middle East Respiratory syndrome diseases. Furthermore, the present study showed that less experienced pharmacists believed less that AZM could treat COVID-19 disease and believed more of the negative consequences of using AZM in viral infections. However, in (B), the numbers of AZM packs sold during COVID without or with prescription were not significantly different. |
